VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
VolitionRx released data showing its Nu.Q Cancer Assay offers significant prognostic value for newly diagnosed lung cancer patients, enabling better risk stratification and treatment selection. The company completed clinical certification at Hospices Civils de Lyon and plans to submit a reimbursement dossier in France shortly, with a determination mandated within five months of admissibility.
Key figures
- Revenue per test est
- €50
- Reimbursement timeline months
- 5
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.